A prospective longitudinal study of Pasireotide in Nelson ’s syndrome

ConclusionsPasireotide lowers plasma ACTH levels in patients with Nelson ’s syndrome. A longer period of treatment may be needed to assess the effects of pasireotide on tumor volume.Trial registration: Clinical Trials.gov ID, NCT01617733
Source: Pituitary - Category: Endocrinology Source Type: research